Age-Related Macular Degeneration
Top Headlines in AMD/Retina: Subretinal drusenoid deposits and CVD risk; combo treatment for maculopathy; and more
In this edition, Iveric Bio is given exclusive permission to develop, commercialize new formulations of Zimura; subretinal drusenoid deposits linked with cardiovascular disease; subcutaneous elamipretide may improve visual function in geographic atrophy; and more.
Unstable retinal thickening may lead to poor visual outcomes during anti-VEGF therapy
NEW YORK — Unstable retinal thickening may contribute to substandard visual outcomes during anti-VEGF treatment, according to a speaker here.
Lower-dose metformin may be linked with reduced AMD risk
NEW YORK — Patients taking lower doses of metformin may be at lower risk for age-related macular degeneration, revealing a potential novel therapy strategy, according to a speaker at the American Society of Retina Specialists meeting.
Patients with AMD may have better outcomes with ForeseeHome monitoring
NEW YORK — Patients with age-related macular degeneration who underwent ForeseeHome monitoring experienced good long-term visual acuity outcomes, according to a study.
Vabysmo for wet AMD shows good visual acuity, anatomic outcomes in real-world study
NEW YORK — A real-world study showed that Vabysmo helps improve visual acuity and anatomic parameters in patients with neovascular age-related macular degeneration.
Iveric Bio given exclusive permission to develop, commercialize new formulations of Zimura
VIDEO: Early detection major area of unmet need in AMD
In this video, Manjot K. Gill, MD, professor of ophthalmology and medical education at Northwestern Feinberg School of Medicine, discusses the challenges that exist in treatment and what future research should focus on.
VIDEO: Strategies to address the growing AMD patient population
In this video, Manjot K. Gill, MD, professor of ophthalmology and medical education at Northwestern Feinberg School of Medicine, discusses rising rates of AMD and what clinicians need to consider to accommodate a growing patient population.
VIDEO: How COVID-19 pandemic impacted AMD treatment follow-up
In this video, Manjot K. Gill, MD, professor of ophthalmology and medical education at Northwestern Feinberg School of Medicine, discusses the impact COVID has had on the delivery of treatment.
VIDEO: Treatment advancements in wet AMD
In these videos, Manjot K. Gill, MD, professor of ophthalmology and medical education at Northwestern Feinberg School of Medicine, discusses the latest treatments for age-related macular degeneration, including Vabysmo (faricimab-svoa, Genentech) and Susvimo (ranibizumab injection, Genentech), formerly known as the Port Delivery System.